XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash Flows Provided by (Used In) Operating Activities    
Net loss before preferred dividends and accretion of Series A preferred stock $ (64,618,000) $ (17,280,000)
Adjustments to reconcile net loss to net cash and restricted cash provided by (used in) operating activities:    
Change in fair value of contingent consideration (280,000) 8,908,000
Loss (gain) from equity method investees 19,000.0 (306,000)
Loss on option exercise 52,348,000 0
Depreciation and amortization expenses 24,058,000 29,503,000
Stock-based compensation expense 11,081,000 18,786,000
Deferred tax expense 295,000 181,000
Amortization of contract cost assets 1,237,000 1,205,000
Amortization of deferred financing costs 1,154,000 882,000
Loss on lease termination 1,906,000 0
Change in tax receivables agreement liability 0 173,000
Right-of-use operating assets 408,000 1,193,000
Other current operating cash inflows (outflows), net 2,000 6,000
Changes in assets and liabilities, net of acquisitions:    
Accounts receivable, net and contract assets (15,815,000) 19,009,000
Prepaid expenses and other current and non-current assets (7,729,000) 7,166,000
Contract cost assets (1,193,000) (1,556,000)
Accounts payable 3,264,000 (8,421,000)
Accrued liabilities (18,879,000) 10,635,000
Operating lease liabilities (2,820,000) (2,582,000)
Accrued compensation and employee benefits 2,195,000 (27,279,000)
Deferred revenue 2,510,000 160,000
Reserve for claims and performance-based arrangements 15,137,000 (35,409,000)
Other long-term liabilities 285,000 (65,000)
Net cash and restricted cash provided by operating activities 4,565,000 4,909,000
Cash Flows Used In Investing Activities    
Cash paid for asset acquisitions and business combinations (4,498,000) (1,385,000)
Purchases of investments and contributions to equity method investees 0 (3,000,000)
Investments in internal-use software and purchases of property and equipment (8,595,000) (5,347,000)
Net cash and restricted cash used in investing activities (13,093,000) (9,732,000)
Cash Flows (Used In) Provided by Financing Activities    
Changes in working capital balances related to claims processing (41,476,000) 37,520,000
Payment of contingent consideration 0 (3,755,000)
Proceeds from stock option exercises 0 1,058,000
Proceeds from issuance of long-term debt, net of offering costs 221,000,000 (529,000)
Repayment of long-term debt (62,500,000) 0
Payment of preferred dividends (4,577,000) (5,078,000)
Taxes withheld and paid for vesting of equity awards (4,593,000) (14,334,000)
Net cash and restricted cash provided by financing activities 107,854,000 14,882,000
Effect of exchange rate on cash and cash equivalents and restricted cash 23,000 (38,000)
Net (decrease) increase in cash and cash equivalents and restricted cash 99,349,000 10,021,000
Cash and cash equivalents and restricted cash as of beginning-of-period 178,496,000 223,457,000
Cash and cash equivalents and restricted cash as of end-of-period $ 277,845,000 $ 233,478,000